Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (4): 673-679. doi: 10.19723/j.issn.1671-167X.2024.04.021

Previous Articles     Next Articles

Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma

Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG*()   

  1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
  • Received:2024-03-16 Online:2024-08-18 Published:2024-07-23
  • Contact: Shudong ZHANG E-mail:zhangshudong@bjmu.edu.cn
  • Supported by:
    Peking University Third Hospital Haidian Innovation and Transformation Project(HDCXZHKC2021208)

RICH HTML

  

Abstract:

Objective: To predict the 3-year cancer-specific survival (CSS) of patients with non-metastatic T3a renal cell carcinoma after surgery. Methods: A total of 336 patients with pathologically confirmed T3a N0-1M0 renal cell carcinoma (RCC) who underwent surgical treatment at the Department of Urology, Peking University Third Hospital from March 2013 to February 2021 were retrospectively collected. The patients were randomly divided into a training cohort of 268 cases and an internal validation cohort of 68 cases at an 4 ∶ 1 ratio. Using two-way Lasso regression, variables were selected to construct a nomogram for predicting the 3-year cancer-specific survival (CSS) of the patients with T3aN0-1M0 RCC. Performance assessment of the nomogram included evaluation of discrimination and calibration ability, as well as clinical utility using measures such as the concordance index (C-index), time-dependent area under the receiver operating characteristic curve [time-dependent area under the curve (AUC)], calibration curve, and decision curve analysis (DCA). Risk stratification was determined based on the nomogram scores, and Kaplan-Meier survival analysis and Log-rank tests were employed to compare progression-free survival (PFS) and cancer-specific survival (CSS) among the patients in the different risk groups. Results: Based on the Lasso regression screening results, the nomogram was constructed with five variables: tumor maximum diameter, histological grading, sarcomatoid differentiation, T3a feature, and lymph node metastasis. The baseline data of the training and validation sets showed no statistical differences (P>0.05). The consistency indices of the column diagram were found to be 0.808 (0.708- 0.907) and 0.903 (0.838-0.969) for the training and internal validation sets, respectively. The AUC values for 3-year cancer-specific survival were 0.843 (0.725-0.961) and 0.923 (0.844-1.002) for the two sets. Calibration curves of both sets demonstrated a high level of consistency between the actual CSS and predicted probability. The decision curve analysis (DCA) curves indicated that the column diagram had a favorable net benefit in clinical practice. A total of 336 patients were included in the study, with 35 cancer-specific deaths and 69 postoperative recurrences. According to the line chart, the patients were divided into low-risk group (scoring 0-117) and high-risk group (scoring 119-284). Within the low-risk group, there were 16 tumor-specific deaths out of 282 cases and 36 postoperative recurrences out of 282 cases. In the high-risk group, there were 19 tumor-specific deaths out of 54 cases and 33 post-operative recurrences out of 54 cases. There were significant differences in progression-free survival (PFS) and cancer-specific survival (CSS) between the low-risk and high-risk groups (P < 0.000 1). Conclusion: A nomogram model predicting the 3-year CSS of non-metastatic T3a renal cell carcinoma patients was successfully constructed and validated in this study. This nomogram can assist clinicians in accurately assessing the long-term prognosis of such patients.

Key words: Renal cell carcinoma, Nomograms, Prognosis

CLC Number: 

  • R737.11

Table 1

Comparison of patients characteristics between training dataset and validation dataset"

Items Total (n=336) Training cohort (n=268) Validation cohort (n=68) P
Age/years, n (%) 0.900
  ≥65 133 (39.6) 107 (39.9) 26 (38.2)
  <65 203 (60.4) 161 (60.1) 42 (61.8)
Gender, n (%) 0.097
  Male 226 (67.3) 186 (69.4) 40 (58.8)
  Female 110 (32.7) 82 (30.6) 28 (41.2)
Laterality, n (%) 0.594
  Left 193 (57.4) 152 (56.7) 41 (60.3)
  Right 143 (42.6) 116 (43.3) 27 (39.7)
Size/cm, n (%) 0.628
  <7 156 (46.4) 123 (45.9) 33 (48.5)
  7≤Size<10 101 (30.1) 79 (29.5) 22 (32.4)
  ≥10 79 (23.5) 66 (24.6) 13 (19.1)
Grade, n (%) 0.410
  Ⅰ to Ⅱ 223 (66.4) 175 (65.3) 48 (70.6)
  Ⅲ to Ⅳ 113 (33.6) 93 (34.7) 20 (29.4)
T3a etiology, n (%) 0.903
  PFI/RSI 233 (69.4) 187 (69.8) 46 (67.7)
  RVI 21 (6.3) 17 (6.3) 4 (5.9)
  RVI+PFI/RSI 82 (24.4) 64 (23.9) 18 (26.5)
pN, n (%) 0.580
  0 325 (96.7) 258 (96.3) 67 (98.5)
  1 11 (3.3) 10 (3.7) 1 (1.5)
Sarcomatoid features, n (%) 0.594
  No 329 (97.9) 262 (97.8) 67 (98.5)
  Yes 7 (2.1) 6 (2.2) 1 (1.5)
Histology, n (%) 0.453
  ccRCC 297 (88.4) 234 (87.3) 63 (92.7)
  pRCC 13 (3.9) 11 (4.1) 2 (2.9)
  other 26 (7.7) 23 (8.6) 3 (4.4)
NSS, n (%) 0.888
  No 315 (93.8) 252 (94.0) 63 (92.7)
  Yes 21 (6.3) 16 (6.0) 5 (7.4)

Table 2

Single and multivariable analyses of 3-year CSS for T3aN0-1M0 RCC"

VariablesUnivariate analysis Multivariate analysis
P HR (95%CI) P HR (95%CI)
Age/years
  ≥65 Reference
  <65 0.765 1.12 (0.53 - 2.39)
Gender
  Male Reference
  Female 0.572 0.78 (0.33- 1.85)
Laterality
  Left Reference
  Right 0.292 0.65 (0.29- 1.45)
NSS
  No Reference
  Yes 0.508 0.51 (0.07 - 3.76)
Size/cm
  <7 Reference Reference
  7≤Size<10 0.042 0.32 (0.11- 0.96) 0.304 0.55 (0.17 -1.73)
  ≥10 0.230 1.68 (0.72- 3.94) 0.216 1.78 (0.71- 4.45)
Histology
  ccRCC Reference
  pRCC 0.926 0.91 (0.12-6.73)
  Other 0.591 1.39 (0.42-4.64)
Grade
  Ⅰ-Ⅱ Reference Reference
  Ⅲ-Ⅳ <0.001 5.03 (2.20- 11.50) 0.064 2.40 (0.95 - 6.05)
Sarcomatoid Features
  No Reference Reference
  Yes <0.001 9.35 (2.76- 31.64) 0.075 3.26 (0.89 - 11.99)
T3a etiology
PFI/RSI Reference Reference
RVI 0.415 1.87 (0.41- 8.47) 0.641 1.46 (0.30-7.12)
RVI+PFI/RSI <0.001 4.48 (2.03-9.90) 0.037 2.50 (1.06-5.94)
pN
  0 Reference Reference
  1 <0.001 11.11 (4.45- 27.72) 0.001 5.81 (1.98-17.11)

Figure 1

Lasso regression: The variation characteristics of the coefficient of variables (A), the selection process of the optimum value of the parameter λ in the Lasso regression model by cross-validation method (B)"

Figure 2

3-year CSS nomogram for T3aN0-1M0 RCC PFI, perinephric fat invasion; RSI, renal sinus invasion; RVI, renal vein invasion; pN, pathologic N; CSS, cancer specific survival; RCC, renal cell carcinoma."

Figure 3

The effectiveness evaluation and validation of the nanogram A, ROC curve of training cohort; B, ROC curve of validation cohort; C, analysis of precision calibration of training cohort; D, analysis of precision of validation cohort; E, decision curve analysis of training cohort; F, decision curve analysis of validation cohort; ROC, receiver operating characteristic; AUC, area under the curve."

Figure 4

Survival curves stratified by different risk groups A, PFS survival curves for low-risk and high-risk groups; B, CSS survival curves for low-risk and high-risk groups; PFS, progress free survival; CSS, cancer specific survival."

1 Elkassem AA , Allen BC , Sharbidre KG , et al. Update on the role of imaging in clinical staging and restaging of renal cell carcinoma based on the AJCC 8th edition, from the AJR special series on cancer staging[J]. AJR Am J Roentgenol, 2021, 217 (3): 541- 555.
doi: 10.2214/AJR.21.25493
2 Guo P , Wang Y , Han Y , et al. Development and validation of a nomogram to predict postoperative cancer-specific survival of patients with nonmetastatic T3a renal cell carcinoma[J]. Urol Oncol, 2021, 39 (12): 835.e19- 835.e27.
doi: 10.1016/j.urolonc.2021.06.014
3 Musso G , Fallara G , Rosiello G , et al. Differential prognostic value of extrarenal involvement in patients with non-metastatic renal cell cancer[J]. Clin Genitourin Cancer, 2023, 21 (4): e279- e285.e1.
doi: 10.1016/j.clgc.2023.02.008
4 Shah PH , Lyon TD , Lohse CM , et al. Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear-cell renal cell carcinoma[J]. BJU Int, 2019, 123 (2): 270- 276.
doi: 10.1111/bju.14523
5 Li L , Shi L , Zhang J , et al. The critical impact of tumor size in predicting cancer special survival for T3aM0M0 renal cell carcinoma: A proposal of an alternative T3aN0M0 stage[J]. Cancer Med, 2021, 10 (2): 605- 614.
doi: 10.1002/cam4.3629
6 Lam JS , Klatte T , Patard JJ , et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: A multicentre experience[J]. Eur Urol, 2007, 52 (1): 155- 162.
doi: 10.1016/j.eururo.2007.01.106
7 Tan WS , Koelker M , Campain N , et al. Comparison of long-term outcomes for young and healthy patients with cT1a and cT3a renal cell carcinoma treated with partial nephrectomy[J]. Eur Urol Focus, 2023, 9 (2): 333- 335.
doi: 10.1016/j.euf.2022.09.018
8 Chung DY , Kang DH , Kim JW , et al. Comparison of oncologic outcomes between partial nephrectomy and radical nephrectomy in patients who were upstaged from cT1 renal tumor to pT3a renal cell carcinoma: An updated systematic review and meta-analysis[J]. Ther Adv Urol, 2020, 12, 1756287220981508.
9 Deng H , Fan Y , Yuan F , et al. Partial nephrectomy provides equivalent oncologic outcomes and better renal function preservation than radical nephrectomy for pathological T3a renal cell carcinoma: A meta-analysis[J]. Int Braz J Urol, 2021, 47 (1): 46- 60.
doi: 10.1590/s1677-5538.ibju.2020.0167
10 Liu H , Kong QF , Li J , et al. A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma[J]. Transl Androl Urol, 2021, 10 (3): 1170- 1178.
doi: 10.21037/tau-20-1262
11 Liu Z , Yang Z , Li J , et al. Partial versus radical nephrectomy for the treatment of pT3aN0M0 renal cell carcinoma: A propensity score analysis[J]. Asian J Surg, 2023, 46 (9): 3607- 3613.
doi: 10.1016/j.asjsur.2023.04.058
[1] Yuanmei LIU, Yicheng FU, Jingxin HAO, Fuchun ZHANG, Huilin LIU. Construction and validation of a nomogram for predicting in-hospital postoperative heart failure in elderly patients with hip fracture [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 874-883.
[2] Zhicun LI, Tianyu WU, Lei LIANG, Yu FAN, Yisen MENG, Qian ZHANG. Risk factors analysis and nomogram model construction of postoperative pathological upgrade of prostate cancer patients with single core positive biopsy [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 896-901.
[3] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[4] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[5] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[6] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[7] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[8] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[9] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[10] Yun-chong LIU,Zong-long WU,Li-yuan GE,Tan DU,Ya-qian WU,Yi-meng SONG,Cheng LIU,Lu-lin MA. Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 781-792.
[11] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[12] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[13] Dong LAN,Zhuo LIU,Yu-xuan LI,Guo-liang WANG,Xiao-jun TIAN,Lu-lin MA,Shu-dong ZHANG,Hong-xian ZHANG. Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 825-832.
[14] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[15] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!